Drug Approvals
3 Small-Cap Stocks That Hold Plenty of Promise Heading Into 2023
Two of the three members of this trio already have announced positive news developments that have given their shares big lifts.
Put Ionis Pharmaceuticals on Your Watchlist
The shares look attractive but timing is important.
Can Amgen Finally Make an Upside Breakout?
The shares are poised to test the $255-$260 area again.
2 New Oncology Focused Small-Cap Biotechs to Keep an Eye On
Once M&A activity picks up, I could see the biotech sector easily rallying 20% or more.
Harmony Biosciences Could Soon Sing an Uplifting Tune
Here's our trading strategy for the shares.
Markets, BOE's Bailey, Reckless Fed, Obesity, Trading Lilly
The Fed as a whole needs to get their act together. Probably, it would be far better if these folks just piped the heck down.
Bristol-Myers Squibb Is Trending to the Downside
Let's take a look at the charts and indicators.
I Have a Strategy for This Cannabis ETF
Let's review the charts and indicators of MSOS.
As Biogen Surges on Alzheimer Trial Results, Here's How to Play It
BIIB shares have jumped around 50% in early trading activity Wednesday.
Point of No Return, Punishing Mistakes, Gnarly Bond Spread, 2 Possible Catalysts
Plus, we take looks at Eli Lilly and Raytheon Technologies after positive news developments for both companies.